ZNTL stock gains as the FDA lifts clinical hold on studies of its lead candidate, azenosertib, which is being developed for different cancer indications.

In a rough day for PARP inhibitors in ovarian cancer, GSK’s Zejula didn’t deliver a life extension benefit in the final ...

“GSK needs Zejula to be successful as it was the only reason it bought up the US biotech Tesaro for $5.1 billion – and evidence so far has vindicated this bold move by CEO Emma Walmsley.

Let's catch up on the latest news from the stock market. From significant investments to major deals, order wins, and appointments, here’s a quick look at which stocks will be in focus in today ...

Global healthcare company GlaxoSmithKline Pharmaceuticals Ltd on Tuesday (September 3) said it has received an income tax refund of ₹222.23 crore for the assessment year 2022-23, following an order ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

It has been about a month since the last earnings report for GSK (GSK). Shares have added about 10.3% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading ...

GSK Plc’s RSV vaccine has been approved for wider use in adults in Europe in a boost for the UK company’s blockbuster shot. The European Commission recommended GSK’s Arexvy for adults aged ...

Pharmaceutical giant GlaxoSmithKline (GSK) and rival drug manufacturers, including Sanofi, Pfizer and Boehringer Ingelheim, have won the right to an appeal hearing by the Delaware Supreme Court ...

GSK Plc shares rose on Wednesday, buoyed by a US court’s decision to review whether evidence supporting claims that heartburn drug Zantac causes cancer is scientifically sound. The British ...

The notice specifically concerns the acquisition of the Horlicks brand in India from GSK for ₹3,045 crore. Additionally, other GSKCH brands such as Boost, Maltova, and Viva were also added to ...